Erin Dunbar
YOU?
Author Swipe
View article: CTNI-70. TPI 287, WHICH IN COMBINATION WITH BEVACIZUMAB (BEV) HAS SHOWN ACTIVITY IN PATIENTS WITH GLIOBLASTOMA (GBM) AFTER PRIOR THERAPY, TO BE EVALUATED IN A PHASE 2 TRIAL AS WELL AS IN OTHER CNS DISEASES
CTNI-70. TPI 287, WHICH IN COMBINATION WITH BEVACIZUMAB (BEV) HAS SHOWN ACTIVITY IN PATIENTS WITH GLIOBLASTOMA (GBM) AFTER PRIOR THERAPY, TO BE EVALUATED IN A PHASE 2 TRIAL AS WELL AS IN OTHER CNS DISEASES Open
The abeotaxane TPI 287 is a microtubule stabilizing agent with demonstrated safety and preliminary evidence of activity in a Phase 1 combination study with BEV for recurrent GBM. (Goldlust 2024) This trial demonstrated a median overall sur…
View article: E088 Investigating the impact of menopause and its treatment on women with systemic autoimmune rheumatic diseases: the Menopause MATTERs Mixed Methods Research Project
E088 Investigating the impact of menopause and its treatment on women with systemic autoimmune rheumatic diseases: the Menopause MATTERs Mixed Methods Research Project Open
Background/Aims Menopause represents a significant and often overlooked transition in the lives of women, particularly those with systemic autoimmune rheumatic diseases (SARDs), such as lupus. Hormonal fluctuations during menopause may exa…
View article: ‘<i>I still can’t forget those words</i>’: mixed methods study of the persisting impact on patients reporting psychosomatic and psychiatric misdiagnoses
‘<i>I still can’t forget those words</i>’: mixed methods study of the persisting impact on patients reporting psychosomatic and psychiatric misdiagnoses Open
Objectives This research aimed to improve understanding of persisting impacts of patient-reported psychosomatic and psychiatric misdiagnoses on patients with systemic autoimmune rheumatic diseases (SARDs). Methods Mixed methods data from t…
View article: A pilot survey into the landscape of neuro-oncology care in the community
A pilot survey into the landscape of neuro-oncology care in the community Open
Background The complexities of the field of neuro-oncology require multidisciplinary collaboration in order to deliver contemporary comprehensive care. There is increasing awareness that much of neuro-oncology care occurs in the community …
View article: Guiding principles for adult CNS tumor treatment programs
Guiding principles for adult CNS tumor treatment programs Open
Central nervous system (CNS) tumors require specialized care to promote better patient survival outcomes and life quality. Before this paper, there were no published guidelines identifying what constitutes specialized, comprehensive CNS tu…
View article: A feasibility randomized controlled trial of an individually delivered, peer support intervention to reduce the impact of psychosis stigma and discrimination for people with psychosis: the let's talk study
A feasibility randomized controlled trial of an individually delivered, peer support intervention to reduce the impact of psychosis stigma and discrimination for people with psychosis: the let's talk study Open
Background Stigma of mental health conditions hinders recovery and well-being. The Honest, Open, Proud (HOP) program shows promise in reducing stigma but there is uncertainty about the feasibility of a randomized trial to evaluate a peer-d…
View article: MMOD-12 PATHOLOGIC INCIDENCE OF TUMOR POSITIVITY VS ONLY NECROSIS AFTER PRIOR RADIATION IN PATIENTS UNDERGOING SURGICAL EXCISION FOR PRESUMED BRAIN METASTASIS RECURRENCE: INSIGHT FROM A PROSPECTIVE MULTICENTER REGISTRY
MMOD-12 PATHOLOGIC INCIDENCE OF TUMOR POSITIVITY VS ONLY NECROSIS AFTER PRIOR RADIATION IN PATIENTS UNDERGOING SURGICAL EXCISION FOR PRESUMED BRAIN METASTASIS RECURRENCE: INSIGHT FROM A PROSPECTIVE MULTICENTER REGISTRY Open
PURPOSE/OBJECTIVE(S) Determining true recurrence versus necrosis alone after previous radiation therapy (RT) for brain metastasis based on imaging alone is difficult. Proper diagnosis is essential, as further radiation is contraindicated i…
View article: Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors Open
Purpose Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institu…
View article: CTNI-19. RESECTION AND CESIUM-131 RADIATION SOURCES IMBEDDED IN BIO-RESORBABLE COLLAGEN TILES (GAMMATILE™) FOLLOWED BY THE STUPP PROTOCOL IN NEWLY-DIAGNOSED GLIOBLASTOMA: GESTALT TRIAL-IN-PROGRESS UPDATE
CTNI-19. RESECTION AND CESIUM-131 RADIATION SOURCES IMBEDDED IN BIO-RESORBABLE COLLAGEN TILES (GAMMATILE™) FOLLOWED BY THE STUPP PROTOCOL IN NEWLY-DIAGNOSED GLIOBLASTOMA: GESTALT TRIAL-IN-PROGRESS UPDATE Open
OBJECTIVE To evaluate the safety and feasibility of combining resection with immediate initiation of radiation and subsequent Stupp protocol in newly-diagnosed glioblastoma (GBM). BACKGROUND Rapid early local progression (REP) after resect…
View article: CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL
CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL Open
Recurrent glioblastoma (GBM) remains a challenging disease with limited therapeutic options and poor prognosis. SL-701 is a novel immunotherapy composed of synthetic peptides designed to elicit an anti-tumor immune response against the ove…
View article: INNV-05. OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS WITH RADIATION NECROSIS FOLLOWING GAMMATILE BRACHYTHERAPY IMPLANTATION
INNV-05. OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS WITH RADIATION NECROSIS FOLLOWING GAMMATILE BRACHYTHERAPY IMPLANTATION Open
Implantation of collagen tile brachytherapy GammaTile (GT Medical Technologies Tempe, AZ) allows for targeting of radiation to residual malignancy following surgical resection of gross disease. Radiation necrosis (RN) can develop after rad…
View article: A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma
A Novel Approach to Determining Tumor Progression Using a Three-Site Pilot Clinical Trial of Spectroscopic MRI-Guided Radiation Dose Escalation in Glioblastoma Open
Glioblastoma (GBM) is a fatal disease, with poor prognosis exacerbated by difficulty in assessing tumor extent with imaging. Spectroscopic MRI (sMRI) is a non-contrast imaging technique measuring endogenous metabolite levels of the brain t…
View article: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma Open
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. Objective To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (…
View article: CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL
CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL Open
Recurrent glioblastoma (GBM) is an aggressive disease with poor survival and limited treatment options. SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against GBM antigens I…
View article: BIOM-43. THE GENOMIC, TRANSCRIPTOMIC, AND EPIGENOMIC LANDSCAPE OF ISOCITRATE DEHYDROGENASE WILD TYPE GLIOBLASTOMA ACROSS THE AGE CONTINUUM
BIOM-43. THE GENOMIC, TRANSCRIPTOMIC, AND EPIGENOMIC LANDSCAPE OF ISOCITRATE DEHYDROGENASE WILD TYPE GLIOBLASTOMA ACROSS THE AGE CONTINUUM Open
BACKGROUND Older age is a poor prognostic factor for glioblastoma (GBM) patients. We tested whether the intrinsic molecular landscape of the tumor may contribute to this poor prognosis. METHODS In accordance with the 2021 WHO classificatio…
View article: Practical guidance for telemedicine use in neuro-oncology
Practical guidance for telemedicine use in neuro-oncology Open
While the COVID-19 pandemic has catalyzed the expansion of telemedicine into nearly every specialty of medicine, few articles have summarized current practices and recommendations for integrating virtual care in the practice of neuro-oncol…
View article: A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma Open
Background Glioblastomas (GBMs) are aggressive brain tumors despite radiation therapy (RT) to 60 Gy and temozolomide (TMZ). Spectroscopic magnetic resonance imaging (sMRI), which measures levels of specific brain metabolites, can delineate…
View article: Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT)
Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Open
Background Survivorship for those living with primary CNS cancers begins at diagnosis, continues throughout a person’s life, and includes caregivers. Opportunities and challenges exist to advance survivorship care for those living with pri…
View article: CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES
CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES Open
Treatment of glioblastoma (GBM) remains a critical challenge and unmet medical need due to limited treatment options. SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit a target-specific anti-tumor immune re…
View article: RTID-01. PHASE III MULTICENTER RCT OF POST-SURGICAL STEREOTACTIC RADIOTHERAPY VERSUS SURGICALLY TARGETED RADIATION THERAPY FOR THE TREATMENT OF LARGE NEWLY DIAGNOSED BRAIN METASTASES – TRIAL IN PROGRESS
RTID-01. PHASE III MULTICENTER RCT OF POST-SURGICAL STEREOTACTIC RADIOTHERAPY VERSUS SURGICALLY TARGETED RADIATION THERAPY FOR THE TREATMENT OF LARGE NEWLY DIAGNOSED BRAIN METASTASES – TRIAL IN PROGRESS Open
BACKGROUND Resection (R) followed by single- or multi-fraction stereotactic radiosurgery (SRT) of brain metastases (BMs) lowers resection bed recurrence compared to R alone. Nevertheless, for larger BMs, 12-month recurrence rates after R+S…
View article: QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES
QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES Open
The development of brain metastases (BM) is one of the most feared complications of cancer due to the substantial neuro-cognitive morbidity and grim prognosis. In the past decade, targeted therapies and checkpoint inhibitors have demonstra…
View article: CTNI-59. A MULTICENTER OBSERVATIONAL STUDY OF CS-131 SEEDS EMBEDDED IN A COLLAGEN CARRIER TILE FOR NEWLY DIAGNOSED AND RECURRENT OPERABLE INTRACRANIAL NEOPLASMS – TRIAL IN PROGRESS
CTNI-59. A MULTICENTER OBSERVATIONAL STUDY OF CS-131 SEEDS EMBEDDED IN A COLLAGEN CARRIER TILE FOR NEWLY DIAGNOSED AND RECURRENT OPERABLE INTRACRANIAL NEOPLASMS – TRIAL IN PROGRESS Open
BACKGROUND For patients with operable intracranial neoplasms, there are opportunities to augment local control beyond traditional methods, such as external beam radiation therapy. Brachytherapy, the implantation of radioactive sources into…
View article: OTHR-01. SNO 2020 DIVERSITY SURVEY: DEFINING DEMOGRAPHICS, RACIAL BIASES, CAREER SUCCESS METRICS AND A PATH FORWARD FOR THE FIELD OF NEURO-ONCOLOGY
OTHR-01. SNO 2020 DIVERSITY SURVEY: DEFINING DEMOGRAPHICS, RACIAL BIASES, CAREER SUCCESS METRICS AND A PATH FORWARD FOR THE FIELD OF NEURO-ONCOLOGY Open
BACKGROUND Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new journals. Yet, modest improvement in racial/ethnic diversity amongst clinical trial participants,…
View article: CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA
CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GBM) is the most common and aggressive primary brain tumor with median overall survival of 15 months and 5-7 months for patients with newly diagnosed or recurrent disease (nGBM or rGBM), respectively. Selinexor is …
View article: INNV-05. MULTIDISCIPLINARY SPINE ONCOLOGY CARE ACROSS THE DISEASE CONTINUUM - UPDATES FOR THE BEDSIDE AND THE BOARDS
INNV-05. MULTIDISCIPLINARY SPINE ONCOLOGY CARE ACROSS THE DISEASE CONTINUUM - UPDATES FOR THE BEDSIDE AND THE BOARDS Open
In response to the increased prevalence and complexity of metastatic and primary spine oncology, there has been a resultant increase in stakeholders, treatments and outcomes. A subset of the global multidisciplinary authors will present a …
View article: INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC
INNV-27. AN INNOVATIVE VIRTUAL MULTI-INSTITUTIONAL, MULTIDISCIPLINARY NEURO-ONCOLOGY TUMOR BOARD: THE NIH-NOB EXPERIENCE DURING THE COVID-19 PANDEMIC Open
BACKGROUND The American Academy of Neurology Institute and Society for Neuro-Oncology recommend multidisciplinary tumor board (MTB) meetings as a quality metric in neuro-oncology. With the COVID-19 pandemic resulting in travel restrictions…
View article: TRLS-05. A multicenter observational study of Cs-131 seeds embedded in a collagen carrier tile for newly diagnosed and recurrent operable intracranial neoplasms –Trial in progress
TRLS-05. A multicenter observational study of Cs-131 seeds embedded in a collagen carrier tile for newly diagnosed and recurrent operable intracranial neoplasms –Trial in progress Open
Background For patients with operable intracranial neoplasms, there are opportunities to augment local control beyond traditional methods, such as external beam radiation therapy (EBRT),. Brachytherapy, the implantation of radioactive sour…
View article: SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology
SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology Open
Background Neuro-oncology has grown tremendously since 2010, marked by increasing society membership, specialized clinical expertise, and new journals. Yet, modest improvement in racial/ethnic diversity amongst clinical trial participants,…
View article: Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases
Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases Open
Background The development of brain metastases (BM) is one of the most feared complications of cancer due to the substantial neurocognitive morbidity and a grim prognosis. In the past decade, targeted therapies and checkpoint inhibitors ha…
View article: Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma Open
Inhibition of mTORC1 signaling has been shown to diminish growth of meningiomas and schwannomas in preclinical studies, and clinical data suggest that everolimus, an orally administered mTORC1 inhibitor, may slow tumor progression in a sub…